Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years

Metastatic, Cerebral Primitive Neuroectodermal Tumors Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00936156
• Other study ID #: PNET HR+ 5
• Secondary ID: CSET 1329
• Status: Completed
• Phase: Phase 2
• Start date: January 2009
• Est. completion date: January 2012

Study information

• Verified date: June 2020
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 5 Years

Eligibility

Inclusion Criteria:

1. Type of tumor:

• Metastatic medulloblastoma whatever the quality of the initial resection (radiologically visible metastases by MRI and/or CSF invaded by at least one mass of tumoral cells).

• Incompletely resected local medulloblastoma with a residue > 1.5 cm2.

• Anaplastic, large cell medulloblastoma whatever the risk criteria (localized or metastatic, complete or incomplete resection).

• Medulloblastoma with amplification of c-myc or N-myc whatever the risk criteria (local or metastatic, complete or incomplete resection).

• Local and/or metastatic sustentorial PNET.

2. Age at diagnosis of the medulloblastoma of more than 5 years and less than 20 years.

3. Age at diagnosis of S-PNET of more than 10 years and less than 20 years.

4. Nutritional and general status compatible with treatment, Lansky score > 60.

5. Estimated life expectancy > 1 months.

6. Radiographs must be available for the second reading in dicom format on a CD-ROM.

7. Hematological function at diagnosis: PMN > 1.0 x 109/l and platelets > 100 x 109/l.

8. Hepatic function at diagnosis: serum bilirubin < 1.5 times normal value; ASAT and ALAT < 2.5 times normal values; prothrombin time > 50%; fibrinogen > 1.5 g/l.

9. Renal function at diagnosis: serum creatinine according to age in a correctly hydrated child: 1 to 15 years < 65 micromol/l; 15 to 18 years < 110 micromol/l.

10. No organ toxicity (Grade > 2 according to NCI-CTC coding, version 2.0)

11. No other concomitant anti-cancer treatment.

12. No prior anti-cancer therapy.

13. No prior irradiation.

14. Written informed consent signed by both parents or legal guardians

Exclusion Criteria:

1. Failure to comply with one of the inclusion criteria.

2. Severe or life-threatening infection.

3. Uncontrolled active or symptomatic intracranial hypertension.

4. Refusal of parents or legal guardian.

5. Patients incapable of undergoing medical follow-up for geographical, social or mental reasons

Related Conditions & MeSH terms

• Metastatic, Cerebral Primitive Neuroectodermal Tumors
• Neuroectodermal Tumors
• Neuroectodermal Tumors, Primitive

Intervention

Drug:
• Chemotherapy (carboplatin, etoposide, thiotepa)
Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months

Locations

Country	Name	City	State
France	Institut Gustave Roussy	Villejuif

Sponsors (1)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

France,